What is Cyberdyne HAL and how does it read muscle signals?
Cyberdyne is a Japanese robotics company founded in 2004 that makes HAL (Hybrid Assistive Limb), a powered exoskeleton that reads faint bio-electrical signals from the skin to detect intended muscle movement before it occurs. HAL for Medical Use is approved in Japan and has CE marking in Europe. Cyberdyne is listed on the Tokyo Stock Exchange.
What Cyberdyne is
Cyberdyne is a Japanese robotics company founded in 2004 by Professor Yoshiyuki Sankai at the University of Tsukuba. The company shares its name with the fictional company from the Terminator film franchise; Cyberdyne, Japan predates the cultural resonance of that reference and operates under its own corporate name without relation to the fictional entity.
Cyberdyne is listed on the Tokyo Stock Exchange (ticker 7779). The company's primary product is HAL, the Hybrid Assistive Limb.
HAL: bio-electrical signal reading
HAL is a powered lower-body (or full-body in some configurations) exoskeleton distinguished from other exoskeletons by its method of detecting wearer intent. Most exoskeletons detect intent through pressure sensors at joints (detecting weight shift and ground contact) or motion sensors detecting limb position. HAL uses surface electromyography (sEMG): electrodes placed on the skin surface pick up faint bio-electrical signals from the muscles beneath, which represent the neural commands to the muscles before the muscles actually contract.
By reading these signals before muscle contraction occurs, HAL can predict the intended movement and assist it at or near the same moment it is initiated, reducing the perceptible delay between intent and powered assistance. This creates a more natural feel of movement for the wearer compared to pressure-sensor or motion-triggered systems.
The bio-electrical signal detection approach works best when residual neural pathway activity is present (for patients with partial mobility impairment). Patients with complete loss of neural pathway activation produce weaker or absent sEMG signals; HAL's bio-electrical detection provides less benefit in those cases, and the system switches to a more active-assist mode.
Regulatory approvals
HAL for Medical Use (lower limb type) received medical device approval in Japan in 2013. The system received EU CE marking under the Medical Device Regulation, making it available for clinical use in European countries. HAL is used in rehabilitation settings in Japan and Europe for patients with neurological conditions, stroke, spinal cord injury, and neuromuscular diseases.
HAL has not received FDA clearance for use in the United States as of mid-2026. US clinical research has been conducted but clearance for commercial use is not documented at FDA database depth as of mid-2026.
HAL for Labor Support
Cyberdyne also offers HAL for Labor Support, an industrial configuration of the HAL system intended for workers performing physically demanding tasks. The Labor Support version uses the same sEMG-based control but is configured for industrial lifting and carrying tasks rather than clinical rehabilitation.
Not autonomous
HAL is not autonomous. The device detects the wearer's intended movement through bio-electrical signals and provides powered assistance for that intended movement. The wearer initiates and directs every movement; HAL amplifies it. The more sophisticated detection method does not change the fundamental human-in-the-loop nature of the system.
Framework cross-links
For the exoskeleton category umbrella, see what is an exoskeleton. For the bio-electrical detection comparison with pressure-sensor-based systems, see what is Ekso Bionics. The Cyberdyne registry entry at registry.deploy.report/companies/cyberdyne-japan carries institutional depth.
Frequently asked questions
- What is HAL (Hybrid Assistive Limb)?
HAL is a powered exoskeleton made by Cyberdyne Japan that reads bio-electrical signals from the skin surface (surface EMG) to detect the wearer's intended muscle movement before it occurs. The system then provides powered assistance aligned with that detected intent. This bio-electrical detection approach creates more natural movement timing compared to pressure or motion sensor systems.
- Is Cyberdyne the company from Terminator?
No. Cyberdyne, Inc. (Japan) is a robotics company founded in 2004 by Prof. Yoshiyuki Sankai at the University of Tsukuba. It is a separate entity from the fictional Skynet parent company in the Terminator film franchise. The name coincidence is noted but does not reflect any relationship to the fictional corporation.
- Is HAL autonomous?
No. HAL detects the wearer's intended movements through bio-electrical signals and provides powered assistance for those movements. The wearer initiates and directs every action. HAL amplifies human intent but does not generate, plan, or execute any movement independently. The sophisticated signal-reading approach does not change the human-in-the-loop nature of the system.
- Where is HAL approved for use?
HAL for Medical Use received medical device approval in Japan in 2013 and has EU CE marking for clinical use in European countries. HAL is not FDA-cleared for commercial use in the United States as of mid-2026, though US clinical research has been conducted. Clinical use is in Japan and Europe.
- How does bio-electrical signal reading work in HAL?
HAL uses surface electromyography (sEMG) electrodes placed on the skin surface to detect faint electrical signals that the nervous system sends to muscles when planning movement. These signals appear in the skin fractions of a second before the muscles actually contract. HAL detects these pre-contraction signals and initiates powered assistance at the point of intended movement, creating more natural and timely assistance than systems that wait for the mechanical result of muscle contraction.
- Does HAL work for patients with complete paralysis?
HAL's bio-electrical detection works best when residual neural pathway activity is present, producing detectable sEMG signals. For patients with complete loss of the neural pathways (complete motor paralysis with no residual signal), the sEMG detection provides weaker signals or none; the system then defaults to a more active-assist mode based on scheduled movement patterns. HAL provides the most benefit for patients with partial mobility impairment where neural pathway activity, even if insufficient for independent walking, produces detectable signals.
Cyberdyne Japan founding (2004, Tsukuba, founder Prof. Yoshiyuki Sankai) verified at company history and academic publication depth. Tokyo Stock Exchange listing (7779) verified at exchange listing depth. Japan medical device approval (2013) and EU CE marking verified at regulatory database and company disclosure depth. FDA clearance absence (US) verified at FDA 510(k) database depth as of mid-2026. Surface EMG bio-electrical signal detection approach verified at peer-reviewed publication and product specification depth. HAL for Labor Support configuration verified at product specification depth. How DEPLOY verifies →